Stock Research: Insulet

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Insulet

NSQ:PODD US45784P1012
23
  • Value
    27
  • Growth
    41
  • Safety
    Safety
    70
  • Combined
    44
  • Sentiment
    13
  • 360° View
    360° View
    23
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Insulet Corporation is a medical device company specializing in continuous insulin delivery systems. It operates in the medical device industry, with its primary product being the Omnipod System. The company serves people with insulin-dependent diabetes and also produces pods for Amgen's Neulasta Onpro kit. In the last fiscal year, the company had a market cap of $20,451 million, profits of $1,446 million, revenue of $2,072 million, and 3900 employees.

more

ANALYSIS: With an Obermatt 360° View of 23 (better than 23% compared with alternatives), overall professional sentiment and financial characteristics for the stock Insulet are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with three out of four metrics below average for Insulet. The only rank that is above average is the consolidated Safety Rank at 70, which means that the company has a financing structure that is safer than those of 70% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the Value, Growth and Sentiment Ranks are all below average. The consolidated Value Rank has a less desirable rank of 27, which means that the share price of Insulet is on the high side compared with typical size in indicators such as revenues, profits, and invested capital. The consolidated Growth Rank also has a low rank of 41, which implies that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. Finally, the consolidated Sentiment Rank is also low at a rank of 13, which means that professional investors are more pessimistic about the stock than for 87% of alternative investment opportunities. While Safety is strong, it’s not the most critical indicator, so we suggest proceeding with caution if you are considering this stock. ...read more

more
Index
NASDAQ
D.J. US Health Care
D.J. US Medical Equipment
S&P 500
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 10-Aug-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
27 1 4 1
Growth
41 67 71 65
Safety
Safety
70 26 4 16
Sentiment
13 90 90 16
360° View
360° View
23 46 27 10
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
31 80 64 14
Opinions Change
11 50 64 54
Pro Holdings
n/a 88 85 48
Market Pulse
19 69 74 21
Sentiment
13 90 90 16
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
27 1 4 1
Growth
41 67 71 65
Safety Safety
70 26 4 16
Combined
44 4 4 11
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
56 11 18 9
Price vs. Earnings (P/E)
33 9 19 10
Price vs. Book (P/B)
26 8 1 7
Dividend Yield
1 1 1 1
Value
27 1 4 1
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
77 81 73 45
Profit Growth
82 65 85 70
Capital Growth
14 19 46 69
Stock Returns
8 83 43 61
Growth
41 67 71 65
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
49 15 6 15
Refinancing
56 23 9 15
Liquidity
75 81 74 72
Safety Safety
70 26 4 16

Similar Stocks

Discover high‑ranked alternatives to Insulet and broaden your portfolio horizons.

ResMed

NYQ:RMD
Country: USA
Industry: Health Care Equipment
Size: X-Large
Full Stock Analysis

Global Payments

NYQ:GPN
Country: USA
Industry: Other Financial Services
Size: X-Large
Full Stock Analysis

Merck (USA)

NYQ:MRK
Country: USA
Industry: Pharmaceuticals
Size: XX-Large
Full Stock Analysis

Micron

NSQ:MU
Country: USA
Industry: Semiconductors
Size: XX-Large
Full Stock Analysis

Frequently Asked
Questions

The only above-average rank is Safety. All other ranks (Value, Growth, and Sentiment) are below average. As Safety is the least critical rank, there are few positive facts to support this stock.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: